Key facts
- It has raised $14.1M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Guangzhou Yuexiu Industrial Investment Fund Management, Guangzhou Jinkong Fund, Guangzhou Fund, Guangzhou Financial Holdings, Guangzhou Industrial Investment Holding Group.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Baiyunshan Hanfang
- ·The full record, as it builds
Funding rounds
No funding rounds for Baiyunshan Hanfang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Baiyunshan Hanfang
Manufacturer of pharmaceutical products intended to lead the modernization and industrial upgrading of traditional Chinese medicine. The company offers pharmaceutical ingredients, pharmaceutical lipid excipients, and health products, thereby providing TCM raw materials, injectable lipid excipients, and innovative health products to the global pharmaceutical, nutrition, and health industries.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 1998
- Employees
- 300
- Website
- byshf.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Baiyunshan Hanfang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Baiyunshan Hanfang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Baiyunshan Hanfang in its N-PORT filings yet. We sweep new filings monthly.